Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma
- Registration Number
- NCT01786616
- Lead Sponsor
- Catholic University, Italy
- Brief Summary
Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Mild to moderate asthma
- Stable clinical conditions
Exclusion Criteria
- Smokers
- Current therapy with oral steroids
- Exacerbations within the past 3 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Formoterol Formoterol 12 mcg BID for four weeks
- Primary Outcome Measures
Name Time Method Peak Expiratory Flow (PEF) variability PEF has been monitorized during the 4-week treatment period
- Secondary Outcome Measures
Name Time Method Forced Expiratory Volume in 1 sec (FEV1) slope of the dose-response curve to salbutamol At the end of the 4-week treatment period
Trial Locations
- Locations (1)
Catholic University, Pneumology Unit
🇮🇹Rome, Italy